Thu, Apr 17, 2014, 4:42 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Abbott Laboratories Message Board

  • Asmodius1 Asmodius1 Aug 23, 1999 3:48 PM Flag

    pipeline?

    Is there anything in ABT's pipeline that's giong to move the stock? We're still way off and there was some recovery today

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sometimes Abbott serves as a safe haven when the market is down,
      but this increase seems to reflect strength based on projected
      earnings growth.

    • ON my PC I have listed Mutual funds and stocks approx 35 to 40 different and only ABT showed black today .Cyclicals down financials down whats going on?

    • Monday August 30, 3:42 pm Eastern
      Time

      Company Press Release

      BioTime, Inc. Moving From
      Nasdaq to the American
      Stock Exchange, Symbol Changes
      to 'BTX'

      BERKELEY, Calif.--(BW
      HealthWire)--Aug. 30, 1999--BioTime, Inc. (Nasdaq:BTIM -
      news)
      announced today that its common shares have been approved
      for listing on the
      American Stock Exchange (AMEX)
      under the symbol ``BTX''.

      Trading on the AMEX
      is expected to begin on August 31, 1999.


      ``BioTime is looking forward to trading on the AMEX,'' said
      Dr. Paul Segall, BioTime chairman and chief executive
      officer.
      ``We believe that the move to AMEX is a positive
      development for the Company and its shareholders.''


      ``In addition, BioTime shareholders can now look
      forward to increasing sales of Hextend� and the entrance
      of other products
      into clinical trials. Hextend
      is BioTime's physiologically balanced plasma volume
      expander which is approved for the treatment
      of large
      volume blood loss during surgery. It is the only
      commercially available plasma expander that contains
      multiple
      electrolytes, glucose, a physiological buffer and hetastarch.
      Hextend is also completely sterilized to avoid risk of
      infection,'' said
      Dr. Segall.

      Two other BioTime
      products, PentaLyte� and HetaCool(TM), are expected to
      enter clinical trials in the near future.
      PentaLyte
      is a pentastarch-based plasma volume expander
      formulated similarly to Hextend, which may be preferable for
      use in surgeries
      where blood loss is not as great.
      HetaCool is a variant of Hextend formulated to replace the
      entire circulating blood volume at
      near-freezing
      temperatures, allowing prolonged surgery on the heart and brain
      while circulation is arrested. Numerous
      experiments
      using both products have been successfully conducted in
      animals.

      BioTime, headquartered in Berkeley,
      Calif., is engaged in the research and development of
      blood plasma volume expanders,
      and solutions and
      technology for low temperature surgery, organ preservation,
      emergency trauma treatment, and other
      applications.


      The matters discussed in this press release include
      forward-looking statements which are subject to various risks,
      uncertainties
      and other factors that could cause actual results to
      differ materially from the results anticipated. Such
      risks and uncertainties
      include but are not limited
      to results of clinical trials; BioTime's ability to
      obtain FDA and foreign regulatory approval to
      market
      its products; competition from products manufactured
      and sold or being developed by other companies; the
      price of and
      demand for BioTime's products;
      BioTime's ability to negotiate favorable licensing or other
      manufacturing and marketing
      agreements for its products; the
      availability of ingredients used in BioTime products; and the
      availability of reimbursement for
      the cost of BioTime
      products (and related treatment) from government health
      administration authorities, private health coverage
      insurers
      and other organizations. These and other risk factors
      are discussed in BioTime's Annual Report on Form 10-K
      filed
      with the Securities and Exchange Commission.


      Contact:

      BioTime, Inc., Berkeley
      Ronald
      Barkin, 510/845-9535
      www.biotimeinc.com

    • Alan's wife owns ABT. News out over weekend. It won't affect the stock price, but can't hurt to have the most powerful man in the world to own your stock indirectly.

      Go ABT!!

    • Good point... well taken. I think the missing
      element in your arguement, however, is with BTIM being an
      extremely small biotech, their ability to raise independent
      financing for manufacturing facilities off of a biotech
      solution would be next to impossible. ... without some
      sort of track record.

      Let's face it... the
      relationship with ABT/BTIM is a win win situation... ABT gets
      to market propietary solutions for once, and BTIM
      can concentrate on research, which is what they are
      good at.

    • Even if it is breakeven you still have to get it
      because it seems that all companies (including hospitals)
      are trying to minimize the number of vendors they
      deal with. So you would think that a blood volume
      expander would fit well with abt. Of course we don't know
      yet how big a product it will be. Apparently there
      are several volume expander products on the market
      and even though Hextend sounds promising, competitors
      may be able to respond effectively to
      it.

      Licensing the product means that abt doesn't have to tie up
      capital, people and time to make the product on their own
      and abt's competitors can't offer the product as part
      of their portfolio. Abt people and capital can be
      working on those home runs.

      What do you other
      members of the board think?

      By the way, does abt
      have any homeruns in the pipe?

      mt

    • Good point. And if this eleventh product does bring in enough to pay for itself, then one would be foolish not to license it.

    • Thanks for the reply. At this time I don't see
      Hextend putting that many dollars on the abt bottom line
      by itself, but I think is does help abt service the
      hospital accounts that it has and that is very important
      to the abt bottom line. From what I read it looks
      like about 8 million units of this type product are
      used annually but I don't know what the selling price
      is or the margins. At least one of the new Biotime
      products will be a substitute for Hextend and will not
      increase unit sales that much. So right now Hextend looks
      like a small but an important product and of course I
      could be wrong.

      Abbot and all of the other large
      pharmas need lots of singles and doubles or a few
      homeruns. Most of them have over a billion shares out.
      Their history, including abt history, shows that they
      have delivered the products they needed to keep
      growing.

      mt

    • Check out Biotime's home page. Abbot has first
      right of refusal for most of Biotime's new
      products.

      http://www.biotimeinc.com/Products.htm

      Anyone who thinks this is spam, why did ABT give BTIM a
      check for $850,000 and aproximatly 2.5mm+ to date. This
      and other products could do very well for ABT's
      bottom line.

      420

    • er,pe,
      Point taken. However, I can see
      benefits to licensing in certain situations. For example
      it can be a way to quickly get a product to fill a
      void in a product portfolio. Say that a company wants
      their salesmen to be able to offer everything that a
      hospital needs for a particular proceedure. There are
      eleven items required and you only make ten of them. You
      can pick up the eleventh item from someone else today
      and leverage it over your entire hospital sales force
      and sell the whole package.

      Or maybe a product
      represents a new technology and in the small print the
      agreement gives you access to that technology or to future
      products. Are there other products on the way after
      Hextend?

      Your thoughts?

      mt

    • View More Messages
 
ABT
38.93+0.55(+1.43%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.